
Panelists challenge the belief that testosterone fuels prostate cancer, explain PSA on therapy and TRAVERSE BPH data, and weigh Schedule III status.
Chicago-The selective endothelin receptor antagonist atrasentan significantly attenuates changes in biochemical markers of bone metabolism and disease progression in a group of patients with advanced hormone-refractory prostate cancer that had progressed on placebo, according to the results of a randomized clinical trial.





